

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

Equality and health inequality impact assessment

**Ibrutinib with R-CHOP for untreated mantle
cell lymphoma when a stem cell transplant
is suitable [ID6596]**

Draft guidance

- 1 Have the potential equality issues identified during the scoping process been addressed by the committee? If so, how?**

No potential equality issues were identified during the scoping process.

- 2 Have the potential health inequality issues identified during the scoping process been addressed by the committee? If so, how?**

No potential health inequality issues were identified during the scoping process.

- 3 Have any other potential equality or health inequality issues been raised in information submitted by stakeholders or in the external assessment report? If so, how has the committee addressed these?**

No equality or health inequality issues were raised by the company, EAG or other stakeholders.

- 4 Have any other potential equality or health inequality issues been identified by the committee? If so, how has the committee addressed these?**

The committee noted that autologous stem cell transplant eligibility criteria typically includes people aged 65 or younger. But, that this is

not an absolute limit in the NHS. Healthcare professionals also consider eligibility based on fitness and clinical assessment. The committee reflected on how changes to the treatment pathway would impact on the eligible population for ibrutinib and requested further information on this in response to consultation.

5 Do the preliminary recommendations make it more difficult for a specific group to access the technology than other groups? If so, what are the barriers to, or difficulties with, access for this group?

No.

6 Has the committee made any reasonable adjustments within its recommendations for the equality issues identified? That is, have any adjustments to the recommendations been made to remove or alleviate barriers to, or difficulties with, access to the technology needed to fulfil NICE's obligations to promote equality.

The committee can only recommend ibrutinib within its marketing authorisation. But, the committee reflected on how changes to the treatment pathway would impact on the eligible population for ibrutinib and requested further information on this in response to consultation.

7 Has the committee taken into consideration the health inequality issues in its decision-making? If so, how was this done?

No health inequality issues were raised.

8 Have the committee's considerations of equality and health inequality issues been described in the draft guidance? If so, where?

Yes, section 3.16.

Approved by senior responsible officer: Adam Brooke

Date: 23/06/2026